Recent advances in COPD disease management with fixed-dose long-acting combination therapies

Expert Review of Respiratory Medicine

Volumn 8, Issue 3, 2014, Pages 357-379

  Bateman, Eric D ^a   Mahler, Donald A ^b   Vogelmeier, Claus F ^c   Wedzicha, Jadwiga A ^d   Patalano, Francesco ^e   Banerji, Donald ^e  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c UNIVERSITY HOSPITAL MARBURG   (Germany)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

chronic obstructive pulmonary disease; combination therapy; exacerbation; inhaled corticosteroids; long acting bronchodilators; lung function; patient reported outcomes

Indexed keywords

ACLIDINIUM BROMIDE; BA 679; BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE; CORTICOSTEROID; FLUTICASONE FUROATE PLUS VILANTEROL; FORMOTEROL; FORMOTEROL FUMARATE PLUS MOMETASONE FUROATE; GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; LAS 40464; OLODATEROL; OLODATEROL PLUS TIOTROPIUM BROMIDE; PLACEBO; PT 003; UMECLIDINIUM; UNCLASSIFIED DRUG; VILANTEROL; BENZYL ALCOHOL DERIVATIVE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHLOROBENZENE; DRUG COMBINATION; ETHANOLAMINE DERIVATIVE; FORMOTEROL FUMARATE; GLYCOPYRRONIUM; INDACATEROL; INDAN DERIVATIVE; MUSCARINIC RECEPTOR BLOCKING AGENT; QUINOLONE DERIVATIVE; QUINUCLIDINE DERIVATIVE; SALBUTAMOL; SALMETEROL XINAFOATE; SCOPOLAMINE DERIVATIVE; TIOTROPIUM BROMIDE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE STUDY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG FUNCTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; DISEASE COURSE; DISEASE MANAGEMENT; DRUG COMBINATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ALBUTEROL; BENZYL ALCOHOLS; BRONCHODILATOR AGENTS; CHLOROBENZENES; DISEASE MANAGEMENT; DISEASE PROGRESSION; DRUG COMBINATIONS; ETHANOLAMINES; FORMOTEROL FUMARATE; GLYCOPYRROLATE; HUMANS; INDANS; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; QUINUCLIDINES; SALMETEROL XINAFOATE; SCOPOLAMINE DERIVATIVES; TIOTROPIUM BROMIDE; TREATMENT OUTCOME;

EID: 84901033058     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2014.910457     Document Type: Review

References (145)

1. Global initiative for chronic Obstructive Lung Disease (GOLD 2014). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2014. Available from: www. goldcopd.org/uploads/ users/files/GOLD-Report-2014.pdf [Last accessed 22 January 2014]
2. Reardon JZ, Lareau SC, ZuWallack R. Functional status and quality of life in chronic obstructive pulmonary disease. Am J Med 2006; 119: 10 (Suppl 1): 32-37.
3. Wedzicha JA, Decramer M, Seemungal TA. The role of bronchodilator treatment in the prevention of exacerbations of COPD. Eur Respir J 2012;40(6):1545-54
4. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009;33(5):1165-85
5. O'Donnell DE, Hernandez P, Kaplan A, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2008 update - highlights for primary care. Can Respir J 2008;15(Suppl A):1A
6. Cazzola M, Dahl R. Inhaled combination therapy with long-acting b2-agonists and corticosteroids in stable COPD. Chest 2004;126(1):220-37
7. Cazzola M, Molimard M. The scientific rationale for combining long-acting b2- agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 2010;23(4): 257-67
8. The COMBIVENT Inhalation Solution Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. Chest 1994;105(5): 1411-19
9. Hanania NA, Donohue JF. Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators. Proc Am Thorac Soc 2007;4(7):526-34
10. Keating GM. Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease. Drugs 2012;72(2): 273-300
11. O'Donnell DE, Flüge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23(6):832-40
12. Steiropoulos P, Tzouvelekis A, Bouros D. Formoterol in the management of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2008;3(2):205-15
13. Stockley RA, Whitehead PJ, Williams MK. Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis. Respir Res 2006;7:147
14. Casaburi R, Kukafka D, Cooper CB, et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005;127(3):809-17
15. Toy EL, Beaulieu NU, McHale JM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med 2011;105(3): 435-41
16. Tashkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary. Respir Res 2013;14:49
17. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356(8):775-89
18. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361(9356):449-56
19. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21(1): 74-81
20. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22(6): 912-19
21. Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007;17(4):CD006829
22. Barnes PJ. Inhaled corticosteroids in COPD: a controversy. Respiration 2010; 80(2):89-95
23. Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009;34(3):641-7
24. Yawn BP, Li Y, Tian H, et al. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. Int J Chron Obstruct Pulmon Dis 2013;8:295-304
25. Barnes PJ. Distribution of receptor targets in the lung. Proc Am Thorac Soc 2004;1: 345-51
26. Meurs H, Dekkers BG, Maarsingh H, et al. Muscarinic receptors on airway mesenchymal cells: novel findings for an ancient target. Pulm Pharmacol Ther 2013; 26(1):145-55
27. Johnson M, Rennard S. Alternative mechanisms for long-acting b2-adrenergic agonists in COPD. Chest 2001;120(1): 258-70
28. Powrie DJ, Wilkinson TM, Donaldson GC, et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J 2007; 30(3):472-8
29. Trevethick M, Clarke N, Strawbridge M, Yeadon M. Inhaled muscarinic antagonists for COPD - does an anti-inflammatory mechanism really play a role? Curr Opin Pharmacol 2009;9(3):250-5.
30. van der Molen T, Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centered outcomes. Prim Care Respir J 2012;21(1):101-8
31. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013;42(6):1484-94
32. Beeh K-M, Korn S, Beier J, et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir Med 2014;doi:10.1016/j. rmed.2014.01.006. [Epub ahead of print]
33. Mahler DA, Decramer M, D'Urzo A, et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: BLAZE study. Eur Respir J 2013;doi: 10.1183/09031936.00124013. [Epub ahead of print]
34. Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med 2013;1(1):51-60
35. Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013;1(3):199-209
36. Dahl R, Gallagher N, Green Y, et al. QVA149 provides a rapid onset of action which is sustained throughout treatment in patients with COPD [abstract P3385]. Eur Respir J 2013;42(Suppl 57):692s
37. Dahl R, Jadayel D, Alagappan VK, et al. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study. Int J Chron Obstruct Pulmon Dis 2013;8:501-8
38. Kerwin EM, Hébert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J 2012;40(5):1106-14
39. Donohue JF, Singh D, Kornmann O, et al. Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis 2011;6:477-92
40. Worth H, Chung KF, Felser JM, et al. Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med 2011;105(4):571-9
41. Ferguson G, Barnes N, Mehta R, et al. Cardio- and cerebro-vascular safety profile Of QVA149 in patients with COPD: a pooled analysis [abstract]. Am J Respir Crit Care Med 2013;187(1):A1488
42. ClinicalTrials.gov Identifier: NCT01574651. Available from: http://clinicaltrials.gov/ct2/show/NCT01574651
43. ClinicalTrials.gov Identifier: NCT01610037. Available from: http://clinicaltrials.gov/show/NCT01610037
44. ClinicalTrials.gov Identifier: NCT01782326. Available from: http://clinicaltrials.gov/show/NCT01782326
45. ClinicalTrials.gov Identifier: NCT01709903. Available from: http://clinicaltrials.gov/show/NCT01709903
46. Celli B, Crater G, Kilbride S, et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest 2014; doi:10.1378/chest.13- 1579. [Epub ahead of print].
47. Donohue JF, Maleki-Yazdi MR, Kilbride S, et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mg in COPD. Respir Med 2013;107(10):1538-46
48. Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umeclidinium/vilanterol compared with umeclidinium or tiotropium in COPD [poster P3640]. Presented at European Respiratory Society Annual Congress; 7-11 September 2013; Barcelona, Spain
49. Anzueto A, Decramer M, Kaelin T, et al. The efficacy and safety of umeclidinium/vilanterol compared with tiotropium in COPD [poster 42837]. Presented at American Thoracic Society International Conference; 17-22 May 2013; Philadelphia, USA
50. ClinicalTrials.gov Identifier: NCT01716520. Available from: http://clinicaltrials.gov/show/NCT01716520
51. GlaxoSmithKline Clinical Study Register. Result summary DB2116133. A randomized, double-blind, 3-way, cross-over study to evaluate lung function response after treatment with umeclidinium 62.5 mcg, vilanterol 25 mcg, and umeclidinium/vilanterol 62.5/25 mcg once-daily in subjects with chronic obstructive pulmonary disease (COPD). 2013. Available from: www. gskclinicalstudyregister. com/files2/a4eb7507- 0808-4196-b85d-70c63e287917 [Last accessed 5 December 2013]
52. Maltais F, Singh S, Donald A, et al. Effects of a combination of vilanterol and umeclidinium on exercise endurance in subjects with COPD: two randomised clinical trials [poster P761]. Presented at European Respiraory Society Annual Congess; 7-11 September 2013; Barcelona, Spain
53. Food and Drug Administration (FDA). FDA Briefing Document. Pulmonary-Allergy Drugs Advisory Committee Meeting. NDA 203-975: umeclidinium and vilanterol inhalation powder for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). 2013. Available from: www.fda.gov/downloads/advisorycommittees/ committeesmeetingmaterials/drugs/pulmonary-allergydrugsadvisorycommittee/ ucm367411.pdf [Last accessed 5 December 2013]
54. Donohue J, Niewoehner D, Brooks J, et al. Long-term safety and tolerability of umeclidinium/vilanterol and umeclidinium in COPD [poster P760]. Presented at European Respiratory Society Annual Congress; 7-11 September 2013; Barcelona, Spain
55. ClinicalTrials.gov Identifier: NCT01777334. Available from: http://clinicaltrials.gov/show/NCT01777334
56. ClinicalTrials.gov Identifier: NCT01899742. Available from: http://clinicaltrials.gov/ct2/show/NCT01899742
57. ClinicalTrials.gov Identifier: NCT01817764. Available from: http://clinicaltrials.gov/ct2/show/NCT01817764
58. ClinicalTrials.gov Identifier: NCT01822899. Available from: http://clinicaltrials.gov/ct2/show/NCT01822899
59. ClinicalTrials.gov Identifier: NCT01879410. Available from: http://clinicaltrials.gov/show/NCT01879410
60. Reisner C, St Rose E, Strom S, et al. Fixed combination of glycopyrrolate and formoterol MDI (GFF-MDI) demonstrates superior inspiratory capacity (IC) compared to tiotropium DPI (Tio) following 7 days dosing, in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD [poster P879]. Presented at European Respiratory Society Annual Congress; 24-28 September 2011; Amsterdam, The Netherlands
61. Reisner C, Fogarty C, Spangenthal S, et al. Novel combination of glycopyrrolate and formoterol MDI (GFF-MDI) provides superior bronchodilation compared to its components administered alone, tiotropium DPI, and formoterol DPI in a randomized, double-blind, placebo-controlled Phase 2b study in patients with COPD [poster]. Presented at American Thoracic Society International Conference; 13-18 May 2011; Denver, Colorado, USA
62. Reisner C, Fogarty C, Spangenthal S, et al. Novel combination of glycopyrrolate and formoterol Mdi (GFF-MDI) provides superior bronchodilation compared to its components administered alone, tiotropium DPI, and formoterol DPI in a randomized, double-blind, placebo-controlled Phase 2b study in patients with COPD [abstract]. Am J Respir Crit Care Med 2011;183(1): A6435.
63. Reisner C, Rennard SI, Fogarty C, et al. Pearl Therapeutics' combination LAMA/LABA MDI (GFF-MDI, PT003) provides a significant benefit on home peak expiratory flow rate (PEFR) and reduces the need for rescue albuterol use compared to its components administered alone, Spiriva Handihaler, and Foradil Aerolizer in a randomized, double-blind, placebo-controlled Phase 2b study in patients with COPD [poster]. Presented at American Thoracic Society International Conference; 18-23 May 2012; San Francisco, California, USA
64. Reisner C, Fernandez C, Orevillo C, et al. Pearl Therapeutics' combination LAMA/LABA MDI (GFF MDI, PT003) provides comparable metabolic and ECG safety to Spiriva HandiHaler and placebo in patients with COPD [poster]. Presented at American Thoracic Society International Conference; 18-23 May 2012; San Francisco, California, USA
65. ClinicalTrials.gov Identifier: NCT01854645. Available from: http://clinicaltrials.gov/show/NCT01854645
66. ClinicalTrials.gov Identifier: NCT01854658. Available from: http://clinicaltrials.gov/show/NCT01854658
67. ClinicalTrials.gov Identifier: NCT01970878. Available from: http://clinicaltrials.gov/ct2/show/NCT01970878
68. Maltais F, Beck E, Webster D, et al. Four weeks once daily treatment with tiotropium +olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients [abstract 5557]. Eur Respir J 2010; 36(Suppl 54): 1014s
69. Aalbers R, Maleki-Yazdi MR, Hamilton A, et al. Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat inhaler in patients with COPD [Poster P2882]. Presented at European Respiratory Society Annual Congress; 1-5 September 2012; Vienna, Austria
70. ClinicalTrials.gov Identifier: NCT01431274. Available from: http://clinicaltrials.gov/show/NCT01431274
71. ClinicalTrials.gov Identifier: NCT01431287. Available from: http://clinicaltrials.gov/show/NCT01431287
72. ClinicalTrials.gov Identifier: NCT01969721. Available from: http://clinicaltrials.gov/ct2/show/NCT01969721
73. ClinicalTrials.gov Identifier: NCT01533935. Available from: http://clinicaltrials.gov/show/NCT01533935
74. ClinicalTrials.gov Identifier: NCT01533922. Available from: http://clinicaltrials.gov/show/NCT01533922
75. ClinicalTrials.gov Identifier: NCT01525615. Available from: http://clinicaltrials.gov/show/NCT01525615
76. Śliwiński P, Perng D-W, Chuchalin A, Jones PW. Efficacy and safety of once-daily aclidinium bromide 200 mg in combination with formoterol in patients with COPD [abstract P137]. Thorax 2010; 65(Suppl 4): A136.
77. ClinicalTrials.gov Identifier: NCT01437397. Available from: http://clinicaltrials.gov/show/NCT01437397
78. Almirall. Press Release: Almirall and Forest Laboratories announce positive results of a Phase III Study for aclidinium and formoterol combination in COPD. 2013. Available from: www.almirall.com/webcorp2/cda/comunicacion- detalle-noticia. jsp?id=2500 [Last accessed 10 January 2014]
79. ClinicalTrials.gov Identifier: NCT01572792. Available from: http://clinicaltrials.gov/show/NCT01572792
80. ClinicalTrials.gov Identifier: NCT01908140. Available from: http://clinicaltrials.gov/ct2/show/NCT01908140
81. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting b2- agonists and corticosteroids. Eur Respir J 2002; 19(1): 182-91
82. Kerwin EM, Scott-Wilson C, Sanford L, et al. A randomised trial of fluticasone furoate/vilanterol (50/25mg; 100/25mg) on lung function in COPD. Respir Med 2013; 107(4):560-9
83. Martinez FJ, Boscia JA, Feldman G, et al. Fluticasone furoate/vilanterol (100/25; 200/25 mg) improves lung function in COPD: a randomised trial. Respir Med 2013; 107(4):550-9
84. Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 2013;1(3):210-23
85. Agusti A, de Teresa L, De Backer W, et al. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD. Eur Respir J 2014;43(3):763-72
86. ClinicalTrials.gov Identifier: NCT01627327. Available from: http://clinicaltrials.gov/show/NCT01627327
87. GlaxoSmithKline Clinical Study Register. Result summary HZC115805. A 12-week study to evaluate the 24-hour pulmonary function profile of fluticasone furoate/vilanterol (FF/VI) inhalation powder 100/25mcg once-daily via a novel dry powder inhaler compared with tiotropium bromide inhalation powder 18mcg delivered once-daily via the HandiHaler in subjects with chronic obstructive pulmonary disease (COPD) who have or are at risk for co-morbid cardiovascular disease. Available from: www.gsk-clinicalstudyregister.com/study/115805?study- ids=115805#rs [Last accessed 14 January 2014]
88. ClinicalTrials.gov Identifier: NCT01551758. Available from: http://clinicaltrials.gov/show/NCT01551758
89. Vestbo J, Anderson J, Brook RD, et al. The study to understand mortality and morbidity in COPD (SUMMIT) study protocol. Eur Respir J 2013; 41(5): 1017-22.
90. ClinicalTrials.gov Identifier: NCT01313676. Available from: http://clinicaltrials.gov/ct2/show/NCT01313676
91. ClinicalTrials.gov Identifier: NCT01706328. Available from: http://clinicaltrials.gov/show/NCT01706328
92. Tashkin DP, Doherty DE, Kerwin E, et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. Int J Chron Obstruct Pulmon Dis 2012; 7: 73-86
93. Calverley PM, Kuna P, Monsó E, et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respir Med 2010;104(12): 1858-68
94. Tzani P, Crisafulli E, Nicolini G, et al. Effects of beclomethasone/ formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients. Int J Chron Obstruct Pulmon Dis 2011;6:503-9
95. Agusti A, Corradi M, Cohuet G, et al. FORWARD: a study of extrafine beclomethasone/formoterol compared with formoterol alone in patients with severe COPD and a history of exacerbations [abstract P762]. Eur Respir J 2013; 42(Suppl 57):141s
96. ClinicalTrials.gov Identifier: NCT00929851. Available from: http://clinicaltrials.gov/show/NCT00929851
97. ClinicalTrials.gov Identifier: NCT01245569. Available from: http://clinicaltrials.gov/ct2/show/NCT01245569
98. Yu AP, Guérin A, Ponce de Leon D, et al. Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. J Med Econ 2011; 14: 486-96.
99. Chapman KR, Fogarty CM, Peckitt C, et al. Delivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPD. Int J Chron Obstruct Pulmon Dis 2011;6:353-63
100. Colthorpe P, Voshaar T, Kiekbusch T, et al. Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long-acting muscarinic antagonist glycopyrronium. J Drug Assess 2013;2: 11-16
101. Pavkov R, Mueller S, Fiebich K, et al. Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol. Curr Med Res Opin 2010;26: 2527-33
102. Svedsater H, Dale P, Garrill K, et al. Qualitative assessment of attributes and ease of use of the ELLIPTATM dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulm Med 2013;13:72
103. Chrystyn H, Niederlaender C. The Genuair inhaler: a novel, multidose dry powder inhaler. Int J Clin Pract 2012;66: 309-17
104. Anderson P. Use of Respimat Soft MistTM inhaler in COPD patients. Int J Chron Obstruct Pulmon Dis 2006;1:251-9
105. Newman SP. Inhaler treatment options in COPD. Eur Respir Rev 2005;14:102-8
106. Witek TJ Jr., Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J 2003;21(2):267-72
107. Jones PW, Beeh KM, Chapman KR, et al. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med 2014;189:250-5
108. Suissa S, Ernst P, Vandemheen KL, Aaron SD. Methodological issues in therapeutic trials of COPD. Eur Respir J 2008;31(5):927-33
109. Global initiative for chronic Obstructive Lung Disease (GOLD 2007). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2007. Available from: www. goldcopd.org/ Guidelines/guidelines-globalstrategy- for-diagnosis-management-2007. html [Last accessed 10 January 2014]
110. Corrado A, Rossi A. How far is real life from COPD therapy guidelines? An Italian observational study. Respir Med 2012; 106(7): 989-97
111. Small M, Broomfield S, Higgins V. Quantification and treatment patterns of real-world patients classified by the GOLD 2011 strategy [abstract P185]. Thorax 2012; 67(Suppl 2):A144-5
112. Jochmann A, Neubauer F, Miedinger D, et al. General practitioner's adherence to the COPD GOLD guidelines: baseline data of the Swiss COPD Cohort Study. Swiss Med Wkly 2010. [Epub ahead of print]
113. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 146(8): 545-55
114. Singh D, Brooks J, Hagan G, et al. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008;63:592-8
115. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180(8): 741-50
116. Pasqua F, Biscione G, Crigna G, et al. Combining triple therapy and pulmonary rehabilitation in patients with advanced COPD: a pilot study. Respir Med 2010; 104(3):412-17
117. Karner C, Cates CJ. Combination inhaled steroid and long-acting beta(2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011; CD008532
118. Bateman ED, Kornmann O, Ambery C, Norris V. Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD. Pulm Pharmacol Ther 2013;26(5): 581-587.
119. Wielders PL, Ludwig-Sengpiel A, Locantore N, et al. A new class of bronchodilator improves lung function in COPD: a trial with GSK961081. Eur Respir J 2013;42(4):972-81
120. Patel S, Marshall S, Summerhill S, et al. The in-vitro pharmacology of PF-4348235 at native receptors - a novel inhaled dual antimuscarinic/beta2 adrenoceptor agonist [abstract]. Am J Respir Crit Care Med 2011;183(1):A1608
121. Philip J, Gray A, Clarke N, et al. Demonstration of dual pharmacology in vivo of PF-3429281: a novel inhaled dual antimuscarinic/beta2 agonist [abstract P1231]. Eur Respir J 2010;36(Suppl 54): 218s
122. Steinfeld T, Hughes AD, Klein U, et al. THRX-198321 is a bifunctional muscarinic receptor antagonist and b2-adrenoceptor agonist (MABA) that binds in a bimodal and multivalent manner. Mol Pharmacol 2011;79(3):389-99
123. Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180(10):948-55
124. Celli B, Decramer M, Leimer I, et al. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010;137(1): 20-30
125. White WB, Cooke GE, Kowey PR, et al. Cardiovascular safety in patients receiving roflumilast for the treatment of chronic obstructive pulmonary disease. Chest 2013; 144(3):758-65
126. Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006;47(12):2554-60
127. Rutten FH, Zuithoff N, Hak E, et al. b-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010;170(10):880-7
128. Søyseth V, Brekke PH, Smith P, Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J 2007;29(2):279-83
129. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359(15):1543-54
130. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010;182(5):598-604
131. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363(12):1128-38
132. Agusti A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012;7(5):e37483
133. Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011;365(13):1184-92
134. Nishimura M, Makita H, Nagai K, et al. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;185:44-52
135. Cazzola M, Page CP, Calzetta L, Matera MG. Emerging anti-inflammatory strategies for COPD. Eur Respir J 2012; 40(3):724-41
136. D'Urzo A. Optimizing the management of chronic obstructive pulmonary disease: applying the GOLD strategy. Clin Pract 2013;10(4):481-92
137. Frampton JE. QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease. Drugs 2014;74:465-88
138. Welte T, Dahl R, Chen H, et al. Once-daily QVA149 improves symptom scores in patients with COPD [abstract P3637]. Eur Respir J 2013;42(Suppl 57): 750s
139. Banerji D, Alagappan V, Green Y, et al. Dual bronchodilation with once-daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD: the IGNITE trials [abstract P3388]. Eur Respir J 2013;42(Suppl 57):693s
140. Barnes N, Hashimoto S, Nagase T, et al. QVA149 provides superior peak lung function in patients with COPD [abstract P3634]. Eur Respir J 2013;42(Suppl 57): 749s
141. Bateman ED, Ferguson GT, Welte T, et al. Dual bronchodilation with once-daily QVA149 significantly improves lung function versus single bronchodilators and salmeterol/fluticasone [abstract]. Am J Respir Crit Care Med 2013;187(1):A4271
142. Welte T, Gallagher N, Green Y, et al. Dual bronchodilation with once-daily QVA149 provides significantly improved clinical outcomes versus mono-bronchodilator therapy: the SHINE study [abstract]. Am J Respir Crit Care Med 2013;187(1):A4272
143. Vogelmeier C, Bateman ED, Chen H, Banerji D. Comparison of COPD exacerbations with once-daily QVA149 versus twice-daily salmeterol/fluticasone combination: the ILLUMINATE study [abstract P237]. Thorax 2013; 68(Suppl 3):A184-5
144. GlaxoSmithKline. FDA Advisory Committee Briefing Document. ANOROTM ELLIPTATM (umeclidinium bromide/vilanterol inhalation powder) for treatment of chronic obstructive pulmonary disease. NDA 203975. Presented to Pulmonary-Allergy Drug Advisory Committee. 2013. Available from: www.fda. gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ Pulmonary-AllergyDrugsAdvisory Committee/UCM367414.pdf [Last accessed 5 December 2013]
145. GlaxoSmithKline Clinical Study Register. Result summary DB2116844. Results report for a meta-analysis of DB2113360 and DB2113374: an integrated review of transitional dyspnoea index data for umeclidinium/vilanterol, umeclidinium, vilanterol and tiotropium over 24 weeks in subjects with COPD. 2013. Available from: www.gsk-clinicalstudyregister.com/files2/1f37e00a-6090- 4648-9a79-4e49e481af40 [Last accessed 5 December 2013]